Short-Term Clinical Response of DEB-TACE Combined with Apatinib on Patient with Intermediate-advanced Hepatocellular Carcinoma
- VernacularTitle:载药微球栓塞联合甲磺酸阿帕替尼治疗中晚期原发性肝癌的近期疗效
- Author:
Yuan WAN
1
;
Bin CHEN
1
;
Nan LI
1
;
Run LIN
1
;
Ke-yu TANG
1
;
Hai-tao DAI
1
;
Chun-yong WEN
1
;
Yong-hui HUANG
1
Author Information
1. Department of Interventional Radiology，The First Affiliated Hospital，Sun Yat-sen University，Guangzhou 510080，China
- Publication Type:Journal Article
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2019;40(3):437-444
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】To evaluate the safety and effects of transcatheter arterial chemoembolization using Drug-eluted beads（DEB-TACE）plus apatinib in patients with hepatocellular carcinoma（HCC）.【Methods】A retrospective analysis was performed，which included 11 HCC patients treated with DEB- TACE and followed by a target therapy of apatinib（500 mg QD）in our clinical research center. Radiograph evaluation and tumor biomarker，alpha- fetoprotein（AFP）， were recorded before the procedure and during the follow-up of the first cycle after 4~8 weeks. Adverse events induced by apatinib were recorded. 【Results】 According to the response evaluation criteria in solid tumors （RECIST），modified response evaluation criteria in solid tumors （mRECIST） and European Association for the study of the liver （EASL） criteria，the objective response rate （ORR） was 36.4% ，63.6% ，72.7% respectively，and the disease control rate（DCR）was 90.7% ，72.7% ，81.8% respectively. AFP levels were 44 251.7 μg/L which significantly decreased after the procedure ，compared to 366 336 μ g/L ，the levels before the treatment. Four reversible grade III adverse events were recorded and no grade IV adverse events found in these cases. 【Conclusion】According to the short-term treatment response and safety，DEB- TACE combined with apatinib could be considered as a promising treatment for intermediate and advanced stage hepatoma.
